miRNAs as potential game-changers in bone diseases: Future medicinal and clinical Uses

AS Doghish, MS Elballal, O Elazazy… - … -Research and Practice, 2023 - Elsevier
Abstract MicroRNAs (miRNAs), short, highly conserved non-coding RNA, influence gene
expression by sequential mechanisms such as mRNA breakdown or translational …

A spotlight on the interplay of signaling pathways and the role of miRNAs in osteosarcoma pathogenesis and therapeutic resistance

AS Doghish, M Hegazy, A Ismail, HA El-Mahdy… - … -Research and Practice, 2023 - Elsevier
Osteosarcoma (OS) is one of the most common bone cancers that constantly affects
children, teenagers, and young adults. Numerous epigenetic elements, such as miRNAs …

From resistance to resilience: Uncovering chemotherapeutic resistance mechanisms; insights from established models

NM Abdelmaksoud, AI Abulsoud, AS Doghish… - … et Biophysica Acta (BBA …, 2023 - Elsevier
Despite the tremendous advances in cancer treatment, resistance to chemotherapeutic
agents impedes higher success rates and accounts for major relapses in cancer therapy …

Recent insights into therapy resistance in osteosarcoma

ZD Prudowsky, JT Yustein - Cancers, 2020 - mdpi.com
Simple Summary Osteosarcoma is the most common cancer of the bone for children and
adolescents. Although chemotherapy regimens have been widely available and effective for …

MicroRNA as a potential therapeutic molecule in cancer

J Szczepanek, M Skorupa, A Tretyn - Cells, 2022 - mdpi.com
Small noncoding RNAs, as post-translational regulators of many target genes, are not only
markers of neoplastic disease initiation and progression, but also markers of response to …

Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm

MA Nengroo, MA Khan, A Verma, D Datta - Biochimica et Biophysica Acta …, 2022 - Elsevier
The oncogenic chemokine duo CXCR4-CXCL12/SDF-1 (CXC Receptor 4-CXC Ligand
12/Stromal-derived factor 1) has been the topic of intense scientific disquisitions since Muller …

Prostate cancer and the cell cycle: focusing on the role of microRNAs

IM Elazab, OA El-Feky, EG Khedr, NE El-Ashmawy - Gene, 2024 - Elsevier
Prostate cancer is the most frequent solid tumor in terms of incidence and ranks second only
to lung cancer in terms of cancer mortality among men. It has a considerably high mortality …

Noncoding RNAs in osteosarcoma: implications for drug resistance

Z Lin, X Xie, S Lu, T Liu - Cancer Letters, 2021 - Elsevier
Osteosarcoma is the most frequent bone malignancy in children and adolescents. Despite
advances of surgery and chemotherapy in osteosarcoma over the past decades, overall …

miR‐21 inhibition reverses doxorubicin‐resistance and inhibits PC3 human prostate cancer cells proliferation

W Zhao, L Ning, L Wang, T Ouyang, L Qi, R Yang… - Andrologia, 2021 - Wiley Online Library
Many approaches have been examined to reversing multidrug resistance (MDR), but sub‐
optimal target‐based strategies have limited their efficacy. Herein, we investigate microRNA …

miRNA-based technologies in cancer therapy

M Pagoni, C Cava, DC Sideris, M Avgeris… - Journal of Personalized …, 2023 - mdpi.com
The discovery of therapeutic miRNAs is one of the most exciting challenges for
pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of …